Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

This study is testing whether a drug called filgotinib can change certain proteins and genetic markers in the blood of people who have active rheumatoid arthritis (RA), a condition where the immune system attacks the joints causing pain and swelling. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with active rheumatoid arthritis based on established medical criteria - Your RA is considered highly active (high disease activity scores) - Your doctor recommends starting filgotinib treatment **You may NOT be eligible if...** - You have previously taken filgotinib or similar JAK inhibitor drugs - You are pregnant or breastfeeding - You have serious infections or conditions that would make this treatment unsafe - You do not meet the activity threshold required for this study Talk to your doctor to see if this trial is right for you.